(2S,1'S,2'R,3'R)-N-[(R)-α-phenylglycinyl]-2-[2'-diethylphosphono-3'-phenylcyclopropyl]glycinonitrile | 939799-58-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物
• 英文名称: (2S,1'S,2'R,3'R)-N-[(R)-α-phenylglycinyl]-2-[2'-diethylphosphono-3'-phenylcyclopropyl]glycinonitrile
• CAS: 939799-58-3
• 化学式: C₂₃H₂₉N₂O₄P
• 分子量: 428.468
• InChiKey: CAXUAJPRTMREGS-BMXMUORJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.25
• 重原子数：
  30.0
• 可旋转键数：
  11.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  91.58
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  (2S,1'S,2'R,3'R)-N-[(R)-α-phenylglycinyl]-2-[2'-diethylphosphono-3'-phenylcyclopropyl]glycinonitrile 在 lead(IV) acetate 、 盐酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 36.33h， 生成 PPCG-4
  参考文献：
  名称：

  Synthesis and preliminary pharmacological evaluation of the four stereoisomers of (2S)-2-(2′-phosphono-3′-phenylcyclopropyl)glycine, the first class of 3′-substituted transC1′−2′-2-(2′-phosphonocyclopropyl)glycines

  摘要：

  Four stereoisomers of (2,S)-2-(2'-phosphono-3-phenylcyclopropyl)glycine were synthesized by a stereocontrolled synthetic procedure and evaluated as mGluRs ligands. The (2S, 1'R,2'S,3'R)-isomer (PPCG-2) showed to be a group III mGluRs selective ligand endowed with a moderate potency as mGluR4/mGluR6 agonist. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.02.040
• 作为产物：
  描述：

  1-bromo-2-phenyl-3-butene 在 间氯过氧苯甲酸 、 pyridinium chlorochromate 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 276.0h， 生成 (2S,1'S,2'R,3'R)-N-[(R)-α-phenylglycinyl]-2-[2'-diethylphosphono-3'-phenylcyclopropyl]glycinonitrile
  参考文献：
  名称：

  Synthesis and preliminary pharmacological evaluation of the four stereoisomers of (2S)-2-(2′-phosphono-3′-phenylcyclopropyl)glycine, the first class of 3′-substituted transC1′−2′-2-(2′-phosphonocyclopropyl)glycines

  摘要：

  Four stereoisomers of (2,S)-2-(2'-phosphono-3-phenylcyclopropyl)glycine were synthesized by a stereocontrolled synthetic procedure and evaluated as mGluRs ligands. The (2S, 1'R,2'S,3'R)-isomer (PPCG-2) showed to be a group III mGluRs selective ligand endowed with a moderate potency as mGluR4/mGluR6 agonist. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.02.040